恩格列净与甘精胰岛素联合应用治疗 2型糖尿病患者的临床研究

Clinical Study on the Treatment of Type 2 Diabetes Patients with the Combination of Englitazone and Insulin Glargine

目的:探讨2型糖尿病患者联合应用恩格列净与甘精胰岛素治疗的临床疗效,并评价药物安全性。方法:将90例2型糖尿病(T2DM)患者选定为本次的研究对象,按照随机的分组方法将其分为联合组和对照组,每组45例。对照组采用甘精胰岛素治疗,联合组在甘精胰岛素的基础上加用恩格列净。对临床疗效进行评价,治疗前后检测患者血糖、血脂水平,记录治疗期间的药物不良反应发生情况。结果:联合组的临床有效率为95.56%(43/45),较对照组的77.78%(35/45)比较,显著提高(P<0.05)。两组治疗后FBG、2hPG以及HbA1c水平均较治疗前降低(P<0.05),联合组上述血糖指标水平治疗后低于对照组(P<0.05)。两组治疗后TC以及TG水平低于治疗前(P<0.05),联合组上述血脂水平治疗后低于对照组(P<0.05)。治疗期间,联合组药物不良反应发生率较对照组降低(P<0.05)。结论:T2DM患者联用恩格列净与甘精胰岛素治疗的疗效显著,血糖及血脂水平控制理想,药物安全性较高,值得进行大力的临床推广。

Objective:To investigate the clinical efficacy and safety of combined use of englitazone and insulin glargine in the treatment of type 2 diabetes.Method:90 patients with type 2 diabetes mellitus(T2DM)were selected as the subjects of this study.They were randomly divided into combined group and control group,with 45 cases in each group.The control group was treated with insulin glargine,and the combined group was treated with englitazin on the basis of insulin glargine.Evaluate the clinical efficacy,detect the blood glucose and blood lipid levels of patients before and after treatment,and record the occurrence of adverse drug reactions during treatment.Result:The clinical effective rate of the combined group was 95.56%(43/45),which was significantly higher than that of the control group 77.78%(35/45),(P<0.05).The levels of FBG,2hPG and HbA1c in the two groups after treatment were lower than those before treatment(P<0.05),and the above blood glucose indexes in the combined group were lower than those in the control group after treatment(P<0.05).The levels of TC and TG in the two groups after treatment were lower than those before treatment(P<0.05),and the above blood lipid levels in the combined group were lower than those in the control group after treatment(P<0.05).During the treatment,the incidence of adverse drug reactions in the combined group was lower than that in the control group(P<0.05).Conclusion:The treatment of T2DM patients with combined use of englitazone and insulin glargine has significant curative effect,ideal control of blood glucose and blood lipid levels,and high drug safety,which is worthy of strong clinical promotion.